ATE348634T1 - Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen - Google Patents

Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen

Info

Publication number
ATE348634T1
ATE348634T1 AT96923299T AT96923299T ATE348634T1 AT E348634 T1 ATE348634 T1 AT E348634T1 AT 96923299 T AT96923299 T AT 96923299T AT 96923299 T AT96923299 T AT 96923299T AT E348634 T1 ATE348634 T1 AT E348634T1
Authority
AT
Austria
Prior art keywords
treatment
solid tumors
vectors
diagnosis
parasites
Prior art date
Application number
AT96923299T
Other languages
English (en)
Inventor
John M Pawelek
David Bermudes
Kenneth B Low
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE348634T1 publication Critical patent/ATE348634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
AT96923299T 1995-06-07 1996-06-05 Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen ATE348634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48642295A 1995-06-07 1995-06-07
US08/658,034 US6190657B1 (en) 1995-06-07 1996-06-04 Vectors for the diagnosis and treatment of solid tumors including melanoma

Publications (1)

Publication Number Publication Date
ATE348634T1 true ATE348634T1 (de) 2007-01-15

Family

ID=27048679

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923299T ATE348634T1 (de) 1995-06-07 1996-06-05 Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen

Country Status (14)

Country Link
US (3) US6190657B1 (de)
EP (1) EP0833660B1 (de)
JP (1) JP3482213B2 (de)
KR (1) KR100435932B1 (de)
CN (1) CN1138563C (de)
AT (1) ATE348634T1 (de)
AU (1) AU719446B2 (de)
BR (1) BR9609016A (de)
CA (1) CA2224075C (de)
DE (1) DE69636777D1 (de)
IL (1) IL122407A (de)
MX (1) MX9709439A (de)
NZ (1) NZ312341A (de)
WO (1) WO1996040238A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
IL132164A0 (en) * 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2002500001A (ja) * 1997-09-10 2002-01-08 ヴァイオン ファーマシューティカルズ、インコーポレーテッド 低下した毒性を有する遺伝子改変腫瘍標的化細菌
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
WO2001025399A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
WO2001024637A1 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
IL148933A0 (en) * 1999-10-04 2002-09-12 Vion Pharmaceuticals Inc Compositions and methods for tumor-targeted delivery of effector molecules
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) * 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
EP2518142B1 (de) * 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
AU2004204751A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
EP1764113A1 (de) * 2003-03-03 2007-03-21 University Of Victoria Innovation And Development Corporation Antikörper gegen Lungenkrebs, Antigene und Verfahren für die Therapie von Lungenkrebs
ES2345200T3 (es) 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7390646B2 (en) 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
JP5618453B2 (ja) * 2003-11-28 2014-11-05 ナショナル リサーチ カウンシル オブ カナダ 抗癌抗体およびその使用
US20070078109A1 (en) * 2004-02-13 2007-04-05 David Platt Compositions and methods used to treat acne and candida
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
CN101022826A (zh) * 2004-06-07 2007-08-22 哈罗尔·戴维·贡 用于癌症治疗的细菌组合物
US8822194B2 (en) 2004-06-29 2014-09-02 Anticancer, Inc. Cancer selective auxotrophs
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
EP1829963A4 (de) 2004-11-24 2009-01-28 Anaeropharma Science Inc Neuer shuttle-vektor
US7785872B2 (en) * 2004-12-08 2010-08-31 Simpson Biotech Co., Ltd. Nucleic acids for enhancing gene expression and use thereof
PT1867714E (pt) * 2005-04-08 2013-12-05 Anaeropharma Science Inc Bactérias resistentes a 5-fluoruracilo e processo para a sua produção
CN101238145B (zh) 2005-06-14 2013-04-24 普罗陶克斯有限公司 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用
BRPI0620693A2 (pt) * 2005-12-15 2016-12-13 Aeras Global Tb Vaccine Found método para suscitar uma resposta imune tanto sistêmica como de mucosa a mycobacteria viva atenuada ou antígenos micobacterianos em um hospedeiro
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2415783B1 (de) * 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
CN101112398A (zh) * 2007-08-28 2008-01-30 罗舒仓 伤寒、副伤寒沙门菌快速抗肿瘤方面的应用
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
JP2011522515A (ja) 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9339018B2 (en) 2009-05-27 2016-05-17 Industry Foundation Of Chonnam National Univeristy Selective infarcted-tissue-targeting bacteria and use thereof
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
EP2697368B1 (de) 2011-04-15 2019-06-05 Genelux Corporation Klonale stämme von abgeschwächten vaccinia-viren und verwendungsverfahren davon
US9901387B2 (en) 2011-05-09 2018-02-27 Innovolink, Llc Apparatus and method for heating adipose cells
US9956028B2 (en) * 2011-05-09 2018-05-01 Innovolink, Llc Apparatus and method for heating biological targets
US9901742B2 (en) 2011-05-09 2018-02-27 Innovolink, Llc Apparatus and method for heating a treatment region with an alternating electric field
US9675814B2 (en) 2011-05-09 2017-06-13 Innovolink, Llc Apparatus and method for obtaining a substantially constant current across a treatment region
EP2764119A2 (de) 2011-10-05 2014-08-13 Genelux Corporation Methoden zum nachweis der replikation oder kolonisierung eines biologischen therapiemittels
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EA030573B1 (ru) 2013-01-02 2018-08-31 Дикой Байосистемз, Инк. Композиции и способы для лечения рака с применением бактерий
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
WO2015076663A1 (en) * 2013-11-22 2015-05-28 Universiti Putra Malaysia (Upm) Salmonella enterica serovar agona for anti-tumor therapy
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3250215B1 (de) 2015-01-29 2025-04-09 Oxyrase, Inc. Verfahren zur hemmung von tumorwachstum
CN105983103B (zh) 2015-03-17 2025-01-07 广州华津医药科技有限公司 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016343860A1 (en) * 2015-10-30 2018-05-10 The Jackson Laboratory Compositions and methods relating to tumor analysis
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018106754A1 (en) 2016-12-07 2018-06-14 Md Biosciences, Inc. Methods of synergistic treatment of cancer
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20180275027A1 (en) * 2017-03-22 2018-09-27 Slmp, Llc Cell yield for synthetic tissue controls and synthetic tissue microarray controls
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3699263A1 (de) * 2019-02-22 2020-08-26 GlaxoSmithKline Biologicals S.A. Gärungsprozess
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
KR20220121245A (ko) 2019-12-26 2022-08-31 살스퍼라, 엘엘씨 고형 종양 암의 치료 방법 및 제제
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
CA2097931C (en) 1990-12-18 2003-07-29 Samuel I. Miller, Iii Salmonella vaccines
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
SK55593A3 (en) 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
IL101409A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Method for the early diagnosis of cancer
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector

Also Published As

Publication number Publication date
US20050036987A1 (en) 2005-02-17
AU719446B2 (en) 2000-05-11
HK1017253A1 (en) 1999-11-19
JP3482213B2 (ja) 2003-12-22
DE69636777D1 (de) 2007-02-01
EP0833660A4 (de) 2003-04-09
CA2224075A1 (en) 1996-12-19
EP0833660A1 (de) 1998-04-08
AU6385196A (en) 1996-12-30
KR100435932B1 (ko) 2004-08-25
US6190657B1 (en) 2001-02-20
CN1138563C (zh) 2004-02-18
IL122407A (en) 2007-09-20
EP0833660B1 (de) 2006-12-20
WO1996040238A1 (en) 1996-12-19
JP2000514400A (ja) 2000-10-31
NZ312341A (en) 1999-05-28
CN1192694A (zh) 1998-09-09
BR9609016A (pt) 1999-07-06
IL122407A0 (en) 1998-06-15
MX9709439A (es) 1998-02-28
US6685935B1 (en) 2004-02-03
CA2224075C (en) 2011-10-04
KR19990022686A (ko) 1999-03-25

Similar Documents

Publication Publication Date Title
DE69636777D1 (de) Vektoren für die diagnose und behandlung von soliden tumoren einschliesslich melanomen
TR200000928T2 (tr) Yeni kombinasyon.
HUT75555A (en) Lactobacillus strains of human origin, their compositions and uses thereof
DE3853558D1 (de) Behandlung von Hyperhidrose und Ichtyosis.
AR244081A1 (es) Composicion para la higiene personal que contiene un surfactante anonico, un anfoterico, y un aducto preparado a partir de aceites vegetales.
WO2003057838A3 (en) Antibodies against the muc18 antigen
DE69827149D1 (de) Agmatin für die behandlung neuropathischer schmerzen
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
TR199900239T2 (de)
DE69003650D1 (de) Aloewasser, herstellungsverfahren und mittel, die dieses enthalten.
CA2186851A1 (en) Use of mycobacteria for the treatment of tumours
DE69827633D1 (de) Oxidationszusammensetzung und verwendungen derselben für die behandlung von keratinischen fasern
FR2471785B1 (de)
ES2023171B3 (es) Procedimiento para estira alambre.
DE69840649D1 (de) Hydrophile zusammensetzung, die eine von vibrio proteolyticus hergestellte protease enthält
ATE156364T1 (de) Verwendung von lectinen für die behandlung von krankheiten
EP0777683A4 (de) Gegen protozoen wirksamezyklische tetrapeptide
UA6318A1 (uk) Штамм frichosporon kashiwayama-продудент речовини, що має стимулюючу дію на репаративні процеси шкіри, і спосіб одержання речовини, що має стимулюючу дію на репаративні процеси шкіри
DE69101847D1 (de) Zubereitung für die Verhütung oder die Behandlung von Hypertriglyceridämie.
TR199800597T1 (xx) Papillum ait deri iltihab� tedavisi ve �nlenmesi.
EP2048235A3 (de) Synthetische Säuger-Alpha-N-Acetylglukosaminidase und die synthetische Säuger-Alpha-N-Acetylglukosaminidase kodierende genetische Sequenzen
DE69625104D1 (de) Verwendung von chemischem Mittel für die Behandlung von Textilien
DK0758342T3 (da) Hidtil ukendt peptidisk aktivt stof og fremstilling heraf
RU97111553A (ru) Штамм бактерий mycobacterium smegmatis вкпм ас-1552, используемый для окисления стеринов растительного и животного происхождения до андрост-4-ен-3,17-диона

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties